References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2023-3-104-110

mrj-1439

Research Article

ОБЗОРЫ

REVIEWS

Принципы уратснижающей терапии: восемь шагов к успеху

Principles of urate-lowering therapy: eight steps to success

https://orcid.org/0000-0002-5394-7869

Желябина

О. В.

Zhelyabina

O. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0003-1191-5831

Елисеев

М. С.

Eliseev

M. S.

Елисеев Максим Сергеевич,

115522, Москва, Каширское шоссе, 34А

Eliseev Maxim Sergeevich,

34A, Kashirskoe Shosse, Moscow 115522

elicmax@yandex.ru

https://orcid.org/0000-0002-6068-3080

Лила

А. М.

Lila

A. M.

115522, Москва, Каширское шоссе, 34А;

кафедра ревматологии,125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522;Department of Rheumatology, 2/1, Barrikadnaya Street, Build. 1, Moscow 125993

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationRussian Federation

2023

13072023

173104110

2023

Желябина О.В., Елисеев М.С., Лила А.М.

Zhelyabina O.V., Eliseev M.S., Lila A.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1439

Лечение такого серьезного системного заболевания, как подагра, зачастую проводится некорректно, несмотря на наличие большого числа рекомендаций и лекарственных препаратов. Нежелание некоторых врачей следовать современным руководствам по ведению больных подагрой является одним из факторов плохой приверженности пациентов терапии. В обзоре рассмотрены современные подходы к лечению подагры, предусматривающие долгосрочное регулирование уровня МК в сыворотке.

Treatment of such a serious systemic disease as gout is often carried out incorrectly, despite the presence of a large number of recommendations and drugs. The reluctance of some doctors to follow current recommendations for the management of patients with gout is one of the factors for poor adherence of patients to therapy. The review considers modern approaches to the treatment of gout, which provide for long-term strategies for lowering of serum uric acid level.

подагралечениесовременные рекомендации

gouttreatmentmodern recommendations

References1

Ofanoa M, Ofanoa SM, Heather M, et al. Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol. Int J Equity Health. 2021 Dec 23;20(1):262. doi: 10.1186/s12939-021-01601-4.

Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765-70. doi:10.1136/annrheumdis-2012-201687

Желябина ОВ, Елисеев МС, Глухова СИ и др. Факторы риска развития сахарного диабета 2-го типа у пациентов с подагрой: результаты проспективного исследования. Современная ревматология. 2022;16(1):52-9. doi: 10.14412/1996-7012-2022-1-52-59.

Zhelyabina OV, Eliseev MS, Glukhova SI, et al. Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022;16(1):52-9. (In Russ.). doi: 10.14412/1996-7012-2022-1-52-59.

Richette P, Perez-Ruiz F, Doherty M, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014 Nov;10(11):654-61. doi: 10.1038/nrrheum.2014.124. Epub 2014 Aug 19.

Gupta MK, Singh JA. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. Drugs. 2019 Apr;79(5):531-41. doi: 10.1007/s40265-019-01081-5.

Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford). 2018 Jan 1; 57(suppl_1):i47-i50. doi: 10.1093/rheumatology/kex432.

Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1431-46. doi: 10.1002/acr.21772.

Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.

Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017 Jul 1;56(7):e1-e20. doi: 10.1093/rheumatology/kex156.

FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020 Jun;72(6):879-95. doi: 10.1002/art.41247. Epub 2020 May 11.

Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014 Feb;29(2): 406-13. doi: 10.1093/ndt/gft378. Epub 2013 Sep 15.

Perez-Ruiz F, Dalbeth N. Combination urate-lowering therapy in the treatment of gout: What is the evidence? Semin Arthritis Rheum. 2019 Feb;48(4):658-68. doi: 10.1016/j.semarthrit.2018.06.004. Epub 2018 Jun 20.

Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007 Aug;46(8):1372-4. doi: 10.1093/rheumatology/kem056a. Epub 2007 May 23.

Елисеев МС, Желябина ОВ. Рациональное использование рекомендаций по применению уратснижающей терапии: клинические примеры. Современная ревматология. 2022;16(3):85-90. doi: 10.14412/1996-7012-2022-3-85-90.

Eliseev MS, Zhelyabina OV. Rational use of recommendations for urate-lowering therapy: clinical examples. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022; 16(3):85-90. (In Russ.). doi: 10.14412/1996-7012-2022-3-85-90.

Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016 Apr;12(4):235-42. doi: 10.1038/nrrheum. 2015.132. Epub 2015 Sep 29.

Kim SC, Newcomb C, Margolis D, et al. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a populationbased cohort study. Arthritis Care Res (Hoboken). 2013 Apr;65(4):578-84. doi: 10.1002/acr.21817.

Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47-56. doi: 10.1016/0002-9343(84)90743-5.

Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011 Feb;63(2):412-21. doi: 10.1002/art.30119.

Елисеев МС, Желябина ОВ, Чикина МН и др. Эффективность фебуксостата у пациентов с подагрой в зависимости от функции почек. РМЖ. Медицинское обозрение. 2022;6(3):140-7.

Eliseev MS, Zhelyabina OV, Chikina MN, et al. Efficacy of febuxostat in patients with gout, depending on renal function. RMZh. Meditsinskoe obozrenie. 2022;6(3):140-7. (In Russ.).

Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med. 2002 Sep 15;33(6):774- 97. doi: 10.1016/s0891-5849(02)00956-5.

Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005 Mar 4;76(16): 1835-47. doi: 10.1016/j.lfs.2004.10.031. Epub 2005 Jan 18.

Alexander SP, Fabbro D, Kelly E, et al. The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S272-S359. doi: 10.1111/bph.13877.

Juge PA, Truchetet ME, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017 Oct;84(5):595-8. doi: 10.1016/j.jbspin.2016.09.020. Epub 2016 Nov 4.

Kim SH, Lee SY, Kim JM, et al. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. Korean J Intern Med. 2020 Jul;35(4):998-1003. doi: 10.3904/kjim.2018.423. Epub 2019 Apr 8.

Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

Love BL, Barrons R, Veverka A, et al. Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy. 2010 Jun;30(6): 594-608. doi: 10.1592/phco.30.6.594.

Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020 Nov 28;396(10264):1745-57. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9.

Gao L, Wang B, Pan Y, et al. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis. Clin Cardiol. 2021 Jul; 44(7):907-16. doi: 10.1002/clc.23643. Epub 2021 May 20.

Al-Abdouh A, Khan SU, Barbarawi M, et al. Effects of Febuxostat on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mayo Clin Proc Innov Qual Outcomes. 2020 Aug 5;4(4):434-42. doi: 10.1016/j.mayocpiqo.2020.04.012. eCollection 2020 Aug.

Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022 Jun;81(6):768-79. doi: 10.1136/annrheumdis-2021-221733. Epub 2022 Feb 2.

Dalbeth N, Billington K, Doyle A, et al. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. Arthritis Rheumatol. 2019 Oct;71(10): 1739-46. doi: 10.1002/art.40929. Epub 2019 Aug 12.

Ellmann H, Bayat S, Araujo E, et al. Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits. Arthritis Rheumatol. 2020 Jan;72(1): 150-6. doi: 10.1002/art.41063. Epub 2019 Dec 10.

Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis. Arthritis Rheum. 2011 Dec; 63(12):4002-6. doi: 10.1002/art.30649.

Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9; 440(7081):237-41. doi: 10.1038/nature04516. Epub 2006 Jan 11.

Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care Res (Hoboken). 2019 Mar;71(3):427-34. doi: 10.1002/acr.23607.

Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015 May;82(3):141-3. doi: 10.1016/j.jbspin.2015.01.002. Epub 2015 Mar 14.

Pascart T, Grandjean A, Capon B, et al. Monosodium urate burden assessed with dualenergy computed tomography predicts the risk of flares in gout: a 12-month observational study: MSU burden and risk of gout flare. Arthritis Res Ther. 2018 Sep 17;20(1):210. doi: 10.1186/s13075-018-1714-9.

Dalbeth N, Nicolaou S, Baumgartner S, et al. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol. Ann Rheum Dis. 2018 Mar;77(3):364-70. doi: 10.1136/annrheumdis-2017-212046. Epub 2017 Nov 16.

Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurseled care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018 Oct 20; 392(10156):1403-12. doi: 10.1016/S0140-6736(18)32158-5.

Robinson PC, Dalbeth N, Donovan P. The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring. J Rheumatol. 2018 May;45(5):697-704. doi: 10.3899/jrheum.170199. Epub 2018 Feb 15.

Perez-Gomez MV, Bartsch LA, CastilloRodriguez E, et al. Potential Dangers of Serum Urate-Lowering Therapy. Am J Med. 2019 Apr;132(4):457-67. doi: 10.1016/j.amjmed.2018.12.010. Epub 2019 Jan 3.

Елисеев МС, Новикова АМ. Коморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапии. Терапевтический архив. 2019;91(5):120-8.

Eliseev MS, Novikova AM. Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urat-reducing therapy. Terapevticheskii arkhiv. 2019;91(5):120-8. (In Russ.).

Chikina MN, Elisеev MS, Sheliabina OV. AB0920 Application of the EULAR 2016 Guidelines for urate-lowering therapy in clinical practice (Data of six-month prospective study). Ann Rheum Dis. 2020;79:1761. doi:10.1136/ANNRHEUMDIS-2020-EULAR.5171.

Чикина МН. Профилактика приступов артрита при назначении уратснижающей терапии у больных подагрой. Научно-практическая ревматология. 2018;56(6):760-6.

Chikina MN. Prevention of arthritis attacks when prescribing urate-reducing therapy in patients with gout. Nauchno-prakticheskaya revmatologiya. 2018;56(6):760-6. (In Russ.).

Tilleman JA, Desimone EM II, McAuliffe R. Urate-lowering therapy for prevention and treatment of gout flare. US Pharm. 2017; 42(3):33-7.

Чикина МН, Елисеев МС, Желябина ОВ. Сравнение эффективности и безопасности различных противовоспалительных препаратов при инициации уратснижающей терапии у пациентов с подагрой (предварительные данные). Современная ревматология. 2021;15(2):50-6. doi: 10.14412/1996-7012-2021-2-50-56.

Chikina MN, Eliseev MS, Zhelyabina OV. Comparison of the efficacy and safety of various anti-inflammatory drugs in urate-lowering therapy initiation in patients with gout (preliminary data). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2021; 15(2):50-6. (In Russ.). doi: 10.14412/1996-7012-2021-2-50-56.

Елисеев МС, Чикина МН, Желябина ОВ. Применение колхицина для профилактики острых приступов артрита у пациентов с подагрой при проведении уратснижающей терапии (результаты пилотного исследования). Современная ревматология. 2021;15(4):50-5. doi: 10.14412/1996-7012-2021-4-50-55.

Eliseev MS, Chikina MN, Zhelyabina OV. Colchicine for acute arthritis attacks prevention in patients with gout during urate-lowering therapy (results of a pilot study). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2021;15(4):50-5. (In Russ.). doi: 10.14412/1996-7012-2021-4-50-55.

Major TJ, Topless RK, Dalbeth N, et al. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ. 2018 Oct 10;363:k3951. doi: 10.1136/bmj.k3951.

Желябина ОВ, Елисеев МС, Глухова СИ и др. Факторы, влияющие на развитие сахарного диабета 2-го типа у пациентов с подагрой (результаты многолетнего проспективного исследования). Научно-практическая ревматология. 2022;60(3):374-80.

Zhelyabina OV, Eliseev MS, Glukhova SI, et al. Factors influencing the development of type 2 diabetes mellitus in patients with gout (results of a long-term prospective study). Nauchno-prakticheskaya revmatologiya. 2022; 60(3):374-80. (In Russ.).

Larsson SC, Burgess S, Michaelsson K. Genetic association between adiposity and gout: a Mendelian randomization study. Rheumatology (Oxford). 2018 Dec 1;57(12): 2145-8. doi: 10.1093/rheumatology/key229.

Li X, Meng X, He Y, et al. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study. PLoS Med. 2019 Oct 18;16(10):e1002937. doi: 10.1371/journal.pmed.1002937. eCollection 2019 Oct.

Hori T, Ouchi M, Otani N, et al. The uricosuric effects of dihydropyridine calcium channel blockers in vivo using urate underexcretion animal models. J Pharmacol Sci. 2018 Apr;136(4):196-202. doi: 10.1016/j.jphs.2017.11.011. Epub 2018 Mar 8.

Waldman B, Ansquer JC, Sullivan DR, et al. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol. 2018 Apr;6(4): 310-8. doi: 10.1016/S2213-8587(18)30029-9. Epub 2018 Feb 26.

Паневин ТС, Желябина ОВ, Елисеев МС и др. Уратснижающие эффекты ингибиторов дипептидилпептидазы-4. Сахарный диабет. 2020;23(4):349-56.

Panevin TS, Zhelyabina OV, Eliseev MS, et al. Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. Sakharnyi diabet. 2020; 23(4):349-56. (In Russ.).

Stack AG, Johnson ME, Blak B, et al. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study. BMJ Open. 2019 Aug 28;9(8): e031550. doi: 10.1136/bmjopen-2019-031550.

Чикина МН, Желябина ОВ, Елисеев МС. Влияние уратснижающей терапии на показатели качества жизни у пациентов с подагрой. Современная ревматология. 2021; 15(3):62-8. doi: 10.14412/1996-7012-2021-3-62-68.

Chikina MN, Zhelyabina OV, Eliseev MS. Impact of urate-lowering therapy on quality of life indicators in patients with gout. Sovremen- naya revmatologiya = Modern Rheumatology Journal. 2021;15(3):62-8. (In Russ.). doi: 10.14412/1996-7012-2021-3-62-68.

Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013 Jun; 72(6):826-30. doi: 10.1136/annrheumdis2012-201676. Epub 2012 Jun 7.

Елисеев МС, Чикина МН, Желябина ОВ. Открытое 6-месячное исследование эффективности титрования дозы аллопуринола у пациентов с подагрой в рамках стратегии «лечение до цели». РМЖ. 2022;(6):17-22.

Eliseev MS, Chikina MN, Zhelyabina OV. An open 6-month study of the effectiveness of titration of the dose of allopurinol in patients with gout as part of the "treatment to goal" strategy. RMZh. 2022;(6):17-22. (In Russ.).

The authors declare that there are no conflicts of interest present.